TGA on Panavax
June 21, 2010
1773 suspected Panavax vaccine
side effects have been reported to
the Therapeutic Goods
Administration between Sep 2009
and Apr 2010.
The figures were released as part
of the TGA’s ongoing monitoring of
the national Panavax vaccine
program, also showed that, to date,
8.7 million doses of the adult
vaccine and 370,000 doses of
Panavax Junior have been
administered nationwide since the
inception of the national program
on 30 Sep last year.
The majority of reported side
effects related to adult vaccinations
and included headaches, gastric
upset, soreness, swelling and
redness at the injection site, whilst
only 156 adverse reaction reports
were made for Panavax Junior - the
majority of which pertained to fever
and/or vomiting post injection.
As a result of the figures, the TGA
has reiterated its stance that
Panavax remains a “safe and
effective vaccine for the prevention
of H1N1 influenza”.
More info at www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jun 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jun 10
